Oral Carnitine in Heart Failure Patients
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
About this trial
Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.
Eligibility criteria
Qualifiers
Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome
Stage 1, 2, 3a, 3b, or 4 chronic kidney disease
Age ≥ 18 years
Able to speak and read English
Disqualifiers
Estimated GFR <15 mL/min/1.73m2 or Stage 5 chronic kidney disease
Currently undergoing renal replacement therapy of any kind
Pregnant, breastfeeding or intending pregnancy
History of seizures of any type
Trial design
Treatments tested in this trial
- Levocarnitine
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov